Regeneron Pharmaceuticals, Inc. (REGN)
ROA
Obliczenia
|
2022/Q3 (30 wrz 2022) |
2022/Q2 (30 cze 2022) |
2022/Q1 (31 mar 2022) |
2021/Q4 (31 gru 2021) |
2021/Q3 (30 wrz 2021) |
2021/Q2 (30 cze 2021) |
2021/Q1 (31 mar 2021) |
2020/Q4 (31 gru 2020) |
||
|---|---|---|---|---|---|---|---|---|---|
| Zysk netto (ttm) | w tys. USD | 7 599 300 | 7 915 800 | 10 162 600 | 16 150 600 | 6 995 500 | 6 205 400 | 4 003 800 | 3 513 200 |
| Aktywa razem | w tys. USD | 27 677 800 | 27 205 800 | 26 348 700 | 50 869 600 | 23 671 500 | 21 485 900 | 17 772 200 | 17 163 300 |
| ROA | 27,46% | 29,10% | 38,57% | 31,75% | 29,55% | 28,88% | 22,53% | 20,47% |
2022/Q3 obliczenia
ROA = Zysk netto (ttm) ÷ Aktywa razem
= $7 599 300K ÷ $27 677 800K
= 27,46%
Analiza porównawcza
2022/Q3
Nazwa spółki
Symbol
ROA
Regeneron Pharmaceuticals, Inc.
REGN
27,46%
Arrowhead Pharmaceuticals Inc.
ARWR
-25,44%
Bristol-Myers Squibb Co.
BMY
9,22%
Catalent Inc.
CTLT
4,11%
Cytokinetics Inc
CYTK
-26,22%
Jazz Pharmaceuticals plc
JAZZ
-0,18%
Organon & Co.
OGN
9,69%
Perrigo Company plc
PRGO
-1,00%
United Therapeutics Corp
UTHR
12,24%
Vertex Pharmaceuticals, Inc.
VRTX
24,20%
Zoetis Inc
ZTS
18,14%